ZNTL Zentalis Pharmaceuticals
- 11.650
- -0.060-0.51%
Zentalis Pharmaceuticals News
Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates
Zentalis Pharma Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment
Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments
TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals (ZNTL) Receives a Buy From Stifel Nicolaus
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating
Wedbush Cuts Zentalis to Neutral, Cites Strategy Shift for Ovarian Cancer Drug
Zentalis Hits 52-week Low as Leerink Downgrades on Data for Lead Asset
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating
Akash Tewari's Buy Rating on Zentalis Pharmaceuticals: Analysis of Q3 Results and Future Outlook
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $46
Zentalis Pharma Analyst Ratings
Promising Clinical Data and Strategic Adaptability Bolster Buy Rating for Zentalis Pharmaceuticals: An Analysis of Michael Ulz's Recommendation
Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (ZNTL) and Humana (HUM)
Stifel Nicolaus Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)
Wells Fargo Maintains Overweight on Zentalis Pharma, Lowers Price Target to $50
Zentalis Pharma Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Analysis
Price Target
No Data
